Akers Biosciences Announces Second Quarter Trading

THOROFARE, NJ--(Marketwired - Aug 3, 2017) - Akers Biosciences, Inc. ( NASDAQ : AKER ) ( AIM : AKR.L ), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that sales in the second quarter ended June 30, 2017 were among the strongest since the Company's admission to NASDAQ Capital Market in 2014.

The Company recorded revenues of approximately $1.2 million over the three-month period, representing an increase of approximately 25 percent over the second quarter of 2016, and a 1.8 times increase over the first quarter of 2017. Revenues were derived from product sales in all key geographic regions (U.S., China and Rest of World) and were comprised of sales across Akers Bio's core commercialized product lines including components associated with the Company's PIFA Heparin/PF4 Rapid Assay products for sale internationally, and MPC breathalyzer based products.

Akers Bio intends to file its Form 10-Q containing the financial statements for the three months and six months ended June 30, 2017 after U.S. market close on Monday, August 14, 2017.

Notice of Conference Call

Akers Bio will hold a conference call on Tuesday, August 15, 2017 at 09:00 a.m. Eastern Time to discuss its earnings for the three months and six months ended June 30, 2017. Management will be available during a question-and-answer session.

To participate in the call from within the U.S., please dial 1-800-210-9006 approximately 10 minutes prior to the scheduled start time. International callers should dial 1-719-457-2602. The Conference ID is 7353698. Interested parties can also listen via a live Internet webcast, which can be found at http://public.viavid.com/index.php?id=125855 .

A recording of the call will be available in the Investor Center of the Company's website at http://www.akersbio.com/investor-center .

About Akers Biosciences, Inc.

Akers Bio develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbio.com . Follow us on Twitter @AkersBio .

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.